Arizona is currently home to 1697 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Phoenix, Tucson, Scottsdale and Mesa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults
NCT06742281
Recruiting
The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of symptomatic, RT-PCR-confirmed SARS-CoV-2 infection. The trial will enroll up to 10016 healthy participants.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/14/2025
Locations: Velocity Clinical Research, Phoenix, Phoenix, Arizona
Conditions: COVID-19
Register for Updates
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
NCT06635980
Recruiting
This phase II trial studies how well hypofractionated radiotherapy before (preoperative) or after (postoperative) breast surgery works in treating patients with different types of non-metastatic (has not spread from original tumor site) breast cancer and to determine the outcomes and side effects of this treatment. Radiation therapy is considered an integral part of breast conserving therapy. Hypofractionated radiation therapy is a radiation treatment in which the total dose of radiation is divi... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Anatomic Stage I Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Breast Carcinoma, Triple-Negative Breast Carcinoma
Register for Updates
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
NCT06228326
Recruiting
The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector that is designed to stimulate an anti-tumor immune response through the production of cytokines delivered to the airways of people with advanced solid tumor malignancies affecting the lungs via nebulization. This Phase 1/2, open-label, multicenter, dose escalation and expansion study is designed to evaluate the safety and tolerability of KB707 in adults with with advanced... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: HonorHealth Research Institute, Scottsdale, Arizona
Conditions: Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer, Lung Cancer (NSCLC)
Register for Updates
Intravesical Gem/Doce in Patients With NMIBC
NCT05644041
Recruiting
Intravesical immunotherapy or chemotherapy for non-muscle invasive bladder cancer (NMIBC) is a well-established treatment for preventing or delaying tumor recurrence after tumor resection. For high-risk non-muscle invasive bladder cancer, immunotherapy in the form of intravesical Bacillus Calmette-Guérin (BCG) can be effective as first-line; nevertheless, the response rate to BCG is suboptimal with many patients failing treatment. Following BCG-failure, however, very few effective therapeutic op... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: University of Arizona Cancer Center, Tucson, Arizona
Conditions: Urinary Bladder Cancer
Register for Updates
A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)
NCT04573023
Recruiting
A Global Phase III multicenter, randomized, assessor-blinded, active-controlled designed to evaluate safety and efficacy of study drug for the treatment of the MPS II.
Gender:
ALL
Ages:
All
Trial Updated:
05/14/2025
Locations: Phoenix Children's Hospital, Phoenix, Arizona
Conditions: Mucopolysaccharidosis II
Register for Updates
American Indian Chronic Renal Insufficiency Cohort Study (AI-CRIC Study)
NCT04185844
Recruiting
Despite many advances in our understanding of the natural history and progression of chronic kidney disease (CKD) and cardio vascular disease (CVD) in the parent CRIC study over the past 15 years, important questions about key risk factors for these diseases remain unanswered in the AI population. To address this burden of CKD in AI communities Investigators formed a consortium of investigators with extensive experience in conducting research of chronic diseases including diabetes, cardiovascula... Read More
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
05/14/2025
Locations: NIDDK-Phoenix Epidemiology and Clinical Research, Phoenix, Arizona
Conditions: Diabetes Mellitus, Chronic Kidney Diseases, Heart Diseases, Cardiovascular Diseases
Register for Updates
Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)
NCT06919991
Recruiting
The purpose of the study is to assess the effects of multiple doses of itraconazole (a strong CYP3A4 inhibitor) on single dose PK of casdatifan in healthy adults and to assess the effects of multiple doses of phenytoin (a strong CYP3A4 inducer) on single dose PK of casdatifan in healthy adults.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/13/2025
Locations: Celerion, Tempe, Arizona
Conditions: Healthy Participants
Register for Updates
Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
NCT06843317
Recruiting
CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.
Gender:
ALL
Ages:
Between 60 years and 85 years
Trial Updated:
05/13/2025
Locations: AMR Phoenix, Phoenix, Arizona
Conditions: RSV Infection
Register for Updates
A Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
NCT05914116
Recruiting
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Research Site 111, Tucson, Arizona
Conditions: Advanced Solid Tumors
Register for Updates
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
NCT05911763
Recruiting
This is a prospective, observational, multi-center longitudinal cohort study to describe the real-world effectiveness, safety and treatment usage of efanesoctocog alfa in patients with hemophilia A treated per standard of care in the US and Japan. Patients will be enrolled in the study after the introduction of efanesoctocog alfa in the hemophilia treatment landscape in each study country. Decision to initiate treatment with commercially available efanesoctocog alfa will be made by the treating... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/13/2025
Locations: Banner MD Anderson Cancer Center- Site Number : 8400008, Gilbert, Arizona
Conditions: Hemophilia A
Register for Updates
Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants
NCT06916156
Recruiting
This is an open-label, non-randomized, single-center, repeated i.v. doses, Phase 1 trial to evaluate the pharmacokinetics, safety, and tolerability of a combination of MEM-ANT3310 in healthy adult female and male participants who will undergo a single bronchoalveolar lavage (BAL) via a standardized fiberoptic bronchoscopy to evaluate and compare the pharmacokinetics characteristics of ANT3310 and meropenem (MEM) in plasma and epithelial lining luid (ELF).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/12/2025
Locations: Pulmonary Associates, PA, Phoenix, Arizona
Conditions: Pharmacokinetics Study on Healthy Volunteers Adults
Register for Updates
Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma
NCT06386315
Recruiting
This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually delivered in 12 treatments. Studies have shown indolent lymphoma to be sensitive to radiation treatment,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Indolent Non-Hodgkin Lymphoma, Refractory Indolent Non-Hodgkin Lymphoma
Register for Updates